Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy

Phase 4 Completed 18 enrolled Khon Kaen University

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy of intravitreal bevacizumab injections for treatment of proliferative diabetic retinopathy (PDR) with new dense vitreous hemorrhage (VH) after previous full panretinal photocoagulation (PRP).

Timeline

Start: 2012-08
Primary completion: 2012-12
Completion: 2012-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	1.25 mg	Intravitreal

Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy

Summary

Timeline

Drugs

Indications